This website is intended for Ireland Healthcare Professionals only. Not a Healthcare Professional in Ireland? Click here

Ms B

  • Hot flushes, night sweats
  • On SNRI (venlaflaxine)

Age: 62

Ms A

Menopause symptoms at initiation

  • Hot flushes & night sweats. 3-4 sweats per night & more in daytime.
  • Genitourinary Syndrome of Menopause (GSM)
  • Onset of hot flushes & night sweats: 7 years ago

Medical history and comorbidities

  • Retinal thrombosis 2017
  • Currently prescribed venlaflaxine (for low mood) and topical vaginal oestrogen

Basis for treatment decision

  • Discussed herbal therapy and HRT but patient chose to try fezolinetant

Response to treatment with VEOZA

  • No night sweats

VMS at 5 months of VEOZA treatment

  • No hot flushes at night

  • 1-2 per day

Adverse Events

  • None reported

Clinician’s comments

“The patient is very happy on her treatment and her symptoms are significantly better. After one month of treatment with fezolinetant night sweats had stopped completely. The patient still experiences 1-2 hot flushes during the day but says this is manageable and has reported a significant improvement in her quality of life.”

Fast relief of hot flushes & night sweats.

Fast relief of hot flushes & night sweats. 1 dose a day, no titration.1,2

Genitourinary Syndrome of Menopause (GSM): From the British Menopause Society: previously referred to as urogenital atrophy or vulvovaginal atrophy, the updated NICE menopause guideline 2024 refers to this combination of atrophic changes and symptoms as ‘genitourinary symptoms of the menopause’. Genitourinary Syndrome of Menopause (GSM) is now the internationally accepted term however, reflecting the impact of fluctuating or low levels of estrogen on urogenital tissue quality.

HRT, hormone replacement therapy; VMS, vasomotor symptoms

 

REFERENCES: 1. VEOZA Summary of Product Characteristics. 2. Data on file Data on File: ref 40499


Adverse events should be reported. For Ireland, Healthcare professionals are asked to report any suspected adverse reactions via: HPRA Pharmacovigilance, Website: www.hpra.ie or Astellas Pharma Co. Ltd. Tel:+353 1 467 1555, E-mail: irishdrugsafety@astellas.com.
 

MAT-IE-VEO-2025-00073 January 2026